Private Advisor Group’s Lipocine LPCN Stock Holding History

Private Advisor Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-588	Closed	-$5K	–	3886
2020 Q1	$5K	Buy	+588	New	+$4.65K	﹤0.01%	1415

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Private Advisor Group's LPCN Position: Q2 2020 in Review

Private Advisor Group sold out of Lipocine (LPCN) in Q2 2020, closing a stake of 588 shares — an estimated $5K sold.

Private Advisor Group first reported a position in LPCN in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 33 funds tracked by Wall St. Rank hold LPCN as of Q2 2020.

Private Advisor Group reported no remaining Lipocine position as of Q2 2020 after selling out during the quarter.
Private Advisor Group sold 588 Lipocine shares in Q2 2020, an estimated $5K.
Private Advisor Group first reported a position in Lipocine in Q1 2020 and held it in 1 quarter.
Private Advisor Group's Lipocine position peaked at $5K in Q1 2020.
33 funds tracked by Wall St. Rank held Lipocine as of Q2 2020.

Based on Private Advisor Group's 13F filing for Q2 2020, filed 17 Aug 2020.